ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

HVO Hvivo Plc

21.70
-0.30 (-1.36%)
13 Dec 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hvivo Plc LSE:HVO London Ordinary Share GB00B9275X97 ORD 0.1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.30 -1.36% 21.70 21.50 22.00 21.75 21.75 21.75 713,708 16:35:02
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 56.04M 16.12M 0.0237 9.18 149.68M
Hvivo Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HVO. The last closing price for Hvivo was 22p. Over the last year, Hvivo shares have traded in a share price range of 18.10p to 31.00p.

Hvivo currently has 680,371,877 shares in issue. The market capitalisation of Hvivo is £149.68 million. Hvivo has a price to earnings ratio (PE ratio) of 9.18.

Hvivo Share Discussion Threads

Showing 11726 to 11746 of 11750 messages
Chat Pages: 470  469  468  467  466  465  464  463  462  461  460  459  Older
DateSubjectAuthorDiscuss
13/12/2024
15:01
Sounds a bit desperate to me
malcolmz1
13/12/2024
09:42
Interesting an email I received this morning from the horses mouth.Looks like Mo's on a mission to drum up business.

Dear ,

We are pleased to share that our colleagues at hVIVO have been featured in Nature Communications with a peer-reviewed paper titled “SARS-CoV-2 human challenge reveals single-gene blood transcriptional biomarkers that discriminate early and late phases of acute respiratory viral infections”.
​​​;
This publication builds on the groundbreaking insights from the world’s first COVID-19 characterisation trial we conducted in 2021 in collaboration with Imperial College London, the UK Vaccine Taskforce, the Department of Health and Social Care (DHSC), and the Royal Free London NHS Foundation Trust.

Read the full article here: Nature Communications

The study identified key biomarkers in the blood activated, not only in SARS-CoV-2 infection but also in other respiratory viruses, that can identify and distinguish between the early and late phases of infection. These biomarkers could provide a basis for advancements in infection diagnosis and management in early and late-stage infections.

Human challenge trials allow researchers to observe infection progression, particularly in the early stages, in detail that would not be possible with a traditional field study. Excitingly, the early-stage marker was observable sometimes even before PCR testing confirmed the presence of the virus, suggesting future clinical utility in inferring the infectiousness of a patient early in the infection time-course as well as a potential role in helping stratify patients for antiviral therapy.

We are delighted to see that hVIVO’s impactful contributions during the COVID pandemic continue to enhance understanding of the immune response to SARS-CoV-2 infection and other respiratory viruses.

If you’d like to discuss how our expertise in human challenge trials could help support the clinical development of your drug candidates, or to learn more on our expanded laboratory and site study services, then please reach out at BD@hvivo.com.

Kind regards,​̴3;​
Yamin 'Mo' Khan
CEO

chica1
12/12/2024
14:20
You're now repeating the same dirge, so in the bin for you. I'm all for different opinions, but yours has got a bit excessive now...
troutisout
12/12/2024
11:58
Chica
"How low will the market take the share price"


I think to around 10p

The company newsflow has been as expected.



Oh look, Nexn thread busy, HVO quiet. Looks like 1gw and his mates have moved back to ramping nexn, another with a highly questionable business model (their peers refuse to use the same business model) and several different name changes. The share price there has crashed multiple times over the years.

How many multiple ids do you have 1gw?

sikhthetech
12/12/2024
10:07
ali47fish,
I would say not really new, but news.
However if this biomarker is just out there, not sure of the significance to HVO, if we had some sort of discovery ownership then there might be a value, however I suspect because of the consortium any value in this new biomarker won't be HVO's.
So good news story but no particular relevance to Challenge studies, more to diagnostic companies who can use this new biomarker for tests.

troutisout
12/12/2024
07:48
It's not news,it's filler...

Bottom line for Hvivo right now is how they are going to beat 2024 revenue of £62 million in 2025.
And
If they don't how low will the market take the share price

chica1
12/12/2024
07:28
Yes. COVID/ respiratory diseases are a very popular area of drug development hence why the RSV challenge model is popular with clients. At £10 million + a pop for a challenge study this will bring in plenty of cash going forward.
pogue
12/12/2024
07:25
is this significant and new though
ali47fish
12/12/2024
07:24
A new peer review paper has been published in Nature Communications titled "SARS-CoV-2 human challenge reveals single-gene blood transcriptional biomarkers that discriminate early and late phases of acute respiratory viral infections". This publication builds on the groundbreaking insights from the world's first COVID-19 characterisation trial we conducted in 2021. Please see link to RNS available here: https://www.londonstockexchange.com/news-article/HVO/covid-19-study-published-in-nature-communications/16807788 The study identified key biomarkers in the blood activated, not only in SARS-CoV-2 infection but also in other respiratory viruses, that can identify and distinguish between the early and late phases of infection. These biomarkers could provide a basis for advancements in infection diagnosis and management in early and late-stage infections. Human challenge trials allow researchers to observe infection progression, particularly in the early stages, in detail that would not be possible with a traditional field study. We are delighted to see that hVIVO's impactful contributions during the COVID pandemic continue to enhance understanding of the immune response to SARS-CoV-2 infection and other respiratory viruses. Don't hesitate to contact me should you have any
burtond1
12/12/2024
07:22
COVID/respiratory diseases challenge agent should prove popular with clients
pogue
11/12/2024
19:19
Could be a woman
protrader3
11/12/2024
19:03
Funny I had the impression Pogue was an elderly bloke by his posting here.
I'd have thought his so called colleagues (who apparently he was out on the lash with)would have been filtered🤔28527;

chica1
11/12/2024
18:21
Pogue filtered. Pathetic when someone has blinkers on and won't see alternative views.
protrader3
11/12/2024
17:55
ltbh often quoted but incorrectly.

Actually means: long term buy and hope.

Because very very few people have the knowledge, analysis and resources of Buffett.

yump
11/12/2024
14:40
as long as it takes no rush at all
manc10
11/12/2024
14:11
I suspect you are in for a long wait .. as I was .. I waited for 4 years before selling .
Hope it works out for you .

bossyboss
11/12/2024
14:07
long term not trading simple
manc10
11/12/2024
14:04
And in any case,it's 2025 that's important ..2028 is meaningless at this time .. unless your nuts that is ..
bossyboss
11/12/2024
14:02
quote he is very bullish of getting 100m revenue by 2028 ....me i will be buying few more as time goes by
manc10
11/12/2024
14:00
Huge difference Chica .. but they see what they want to see..
bossyboss
11/12/2024
13:58
He did not say they were on 'track' for 2028 he said 'aiming'
Big difference

chica1
Chat Pages: 470  469  468  467  466  465  464  463  462  461  460  459  Older

Your Recent History

Delayed Upgrade Clock